Semaglutide vs. Tirzepatide vs. Retatrutide: Triple GLP-1 Comparison

EXOMA Scientific Team · Publicado el 8 de mayo de 2026 · Actualizado el 24 de agosto de 2026

Scientific comparison of the three main incretin analogs investigated for weight reduction: Semaglutide, Tirzepatide and Retatrutide.

Mono, Dual, and Triple: the New Generation of Incretin Analogs

The family of incretin peptides has evolved in three leaps of molecular architecture. First came the mono-agonists of the GLP-1 receptor (glucagon-like peptide 1), then the dual-agonists that add the GIP receptor (glucose-dependent insulinotropic polypeptide) and, finally, the triple-agonists that additionally incorporate the glucagon receptor (GCGR). Semaglutide, tirzepatide, and retatrutide represent exactly that arc: one receptor, two receptors, three receptors.

This article compares the three compounds side by side from a technical reference perspective for research work (RUO). It is not a human dosing guide nor a clinical recommendation: it is the comparative sheet a researcher consults before planning reconstitution, storage, and purity controls. For the individual profiles, each section links to its monograph in the compendium.

Master Comparison Table

All three are long-chain peptides stabilized against enzymatic degradation. Note that retatrutide, despite adding a third receptor, has a slightly lower molecular weight than tirzepatide: multi-receptor activity does not depend on gross size, but on the arrangement of key residues in the sequence.

Molecular Differences: What Changes at Each Step

Semaglutide — the Aib substitution at position 8

Semaglutide is a GLP-1 analog with a central modification: the substitution of a natural amino acid with aminoisobutyric acid (Aib) at position 8 of the chain. That position is precisely where the enzyme DPP-4 (dipeptidyl peptidase-4) cleaves native GLP-1. By placing an Aib residue —a non-proteinogenic and sterically hindered amino acid— the molecule becomes resistant to that cleavage, which explains its prolonged stability compared with the endogenous peptide, which degrades within minutes. Added to this is a fatty-acid side chain that promotes reversible binding to albumin, another structural stabilization factor.

Tirzepatide — the incorporation of the GIP arm

Tirzepatide (LY3298176) maintains the logic of a stabilized incretin analog but is designed on a GIP-derived backbone capable of activating both receptors: GIPR and GLP-1R. It is a single peptide that acts as a dual agonist, not a mixture of two molecules. Its reported half-life is approximately 5 days, consistent with an architecture designed for sustained exposure. The addition of the GIP component is the feature that structurally distinguishes it from the mono-agonist generation.

Retatrutide — the third receptor, glucagon

Retatrutide (LY3437943) takes the third step: it is a triple agonist GIPR/GLP-1R/GCGR. It retains the two incretin axes of tirzepatide and adds agonism on the glucagon receptor. This third arm is what introduces the element of greatest mechanistic interest in the entire comparison.

Why Glucagon Adds Thermogenesis

In general physiology —an uncontroversial scientific context— glucagon is not just the hormone "opposite" to insulin that raises hepatic glucose. Glucagon signaling is also associated with an increase in energy expenditure: it activates pathways that increase the basal metabolic rate, a phenomenon described as a thermogenic effect.

The design logic of a triple agonist is to take advantage of that glucagon-mediated thermogenesis while the GLP-1 and GIP arms maintain incretin signaling. In terms of mechanism, the GCGR axis provides an energy-expenditure component that mono- and dual-agonists do not have. This is the central conceptual difference between retatrutide and its predecessors, and the reason why the phase 2 study by Jastreboff (NEJM 2023) drew so much attention in the metabolic research literature. The details of that published evidence are beyond the scope of a product data sheet; here what matters is the architecture, not extrapolating results.

The Published Evidence, in Its Context

Each compound has an associated research program that has been cited in the literature:

• Semaglutide — STEP trial program.
• Tirzepatide — SURMOUNT program.
• Retatrutide — phase 2 data published by Jastreboff and colleagues in NEJM (2023).

We mention these programs solely as bibliographic reference points for the lineage of each molecule. We do not reproduce efficacy figures nor transfer them to a use context: they are study frameworks in specific populations under controlled clinical design, not promises of outcome. A researcher working with these peptides at the bench should turn to the complete primary sources.

Reconstitution Math

The three compounds are usually distributed as a lyophilized powder, a format that stabilizes the peptide for transport and storage. Lyophilization (freeze-drying) removes the water without thermally degrading the chain, and the material must be reconstituted before any experimental work.

The calculation principle is identical for semaglutide, tirzepatide and retatrutide, and independent of the molecule:

$\text{Concentration} = \frac{\text{mass of peptide in the vial}}{\text{volume of solvent added}}$

For example, if a given mass of peptide is reconstituted with a given volume of bacteriostatic water, the resulting concentration is expressed in mg/mL, and from there the volume corresponding to any target quantity is derived. Since the three peptides have distinct molecular weights (4113.58, 4813.45 and 4731.3 Da), the same mass in mg no corresponds to the same number of moles: this matters when comparing molar potencies in experimental design.

To avoid doing the arithmetic by hand, we have dedicated tools:

• La dose calculator converts target mass into volume to be drawn up.
• La vial calculator helps plan how much solvent to add according to the concentration you are targeting.
• El unit converter resolves the mg ↔ mcg ↔ IU conversions.

If this is your first reconstitution, the practical guide to reconstitution of lyophilized peptides and the guide to calculate doses explain the procedure step by step.

Storage

The storage behavior is common to the class:

The operating rule: keep the material lyophilized until the moment of work and reconstitute only the volume that will be used within a reasonable window. Bacteriostatic water as a solvent is the usual choice precisely because its preservative limits microbial growth between withdrawals.

Purity and COA

For reproducible research work, the identity and purity of the peptide are not a minor detail: they are the variable that determines whether a result means anything. The reference technique is HPLC (high-performance liquid chromatography), which separates the intact peptide from fragments, truncations, and synthesis byproducts and allows the purity percentage to be quantified. Identity confirmation is complemented by mass spectrometry, which verifies that the measured molecular weight matches the theoretical value from the master table.

Each batch must be accompanied by its Certificate of Analysis (COA), which states the method, the chromatogram and the reported purity percentage. Before purchasing any of these three peptides, check that the COA corresponds to the batch and that the mass values are consistent with the CAS numbers and formulas above.

Frequently Asked Purchase Questions

Which to choose for a research protocol? It depends on which mechanistic axis one wishes to study: GLP-1 mono-agonism (semaglutide), dual GIP/GLP-1 (tirzepatide), or triple with a glucagon component (retatrutide). The comparator allows their technical parameters to be compared side by side.

Do they come ready to use? No: they are distributed lyophilized and require reconstitution. Check the guides linked above.

Where can I see the complete scientific data sheet? In the compendium: semaglutide, tirzepatide y retatrutide.

How do I verify the quality? Require the COA with HPLC analysis and mass confirmation per lot.

Where do I buy each one? On its product pages: semaglutide, tirzepatide y retatrutide. All three belong to the category metabolism, where you will find the rest of the related catalog.

Conclusion

The progression from mono to dual to triple is not marketing: it is a progression of molecular architecture with well-defined additional receptors. Semaglutide establishes stabilization of the GLP-1 axis through the Aib8 substitution; tirzepatide adds the GIP arm in a single chain; retatrutide adds the glucagon axis and, with it, the thermogenic component that distinguishes it. Understanding these structural differences—and backing them with precise reconstitution, proper storage, and a verified COA—is what separates a reproducible experiment from noisy data.

Explore the full compendium, calculate your reconstitution in the calculator or review the entire product catalog.

Disclaimer: All products are offered exclusively for scientific research (RUO, research use only). The information in this article is technical and educational in nature, does not constitute medical advice or a use recommendation, and should not be interpreted as a dosing guide. Always consult the primary sources and the Certificate of Analysis of the corresponding lot.

Products available at EXOMA

• Retatrutide
• Semaglutide
• Tirzepatide